Amphastar pharmaceuticals reports financial results for the three months ended september 30, 2024

Reports net revenues of $191.2 million for the three months ended september 30, 2024 rancho cucamonga, ca / accesswire / november 6, 2024 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") today reported results for the three months ended september 30, 2024. third quarter highlights net revenues of $191.2 million for the third quarter gaap net income of $40.4 million, or $0.78 per share, for the third quarter adjusted non-gaap net income of $49.6 million, or $0.96 per share, for the third quarter dr. jack zhang, amphastar's president and chief executive officer, commented: "amphastar has continued its growth this quarter, highlighted by sales, particularly from baqsimi®, which has become a cornerstone in our portfolio, and primatene mist®, which is trending toward our goal of $100 million in sales per year.
AMPH Ratings Summary
AMPH Quant Ranking